The FDA has approved Cobenfy (xanomeline and trospium chloride) for treating schizophrenia in adults, marking a breakthrough as the first antipsychotic to target cholinergic receptors instead of dopamine receptors. Schizophrenia, a chronic mental illness affecting about 1% of Americans, causes psychotic symptoms and cognitive difficulties, and is a leading cause of disability globally. Cobenfy’s efficacy was demonstrated in two 5-week clinical trials where participants saw a significant reduction in symptoms. However, it carries warnings for potential side effects, including urinary retention, liver and kidney issues, and is not recommended for patients with certain pre-existing conditions.
Home » FDA Approves Cobenfy: A Breakthrough Antipsychotic with New Mechanism for Schizophrenia Treatment
FDA Approves Cobenfy: A Breakthrough Antipsychotic with New Mechanism for Schizophrenia Treatment
Facebook
Twitter
LinkedIn
Email
WhatsApp
Facebook
Twitter
LinkedIn
Email
WhatsApp
Related Shorts
Dietary Zinc Could Lower Endometriosis Risk
November 2, 2024
Grape Seed Extract for Mood Regulation and Cognitive Health
October 24, 2024
Menthol : A Novel Therapeutic Pathway for Alzheimer’s
October 24, 2024
Vitamin D and Probiotics: A New Strategy for Managing Migraines
October 18, 2024
Spermidine: The Polyamine with Potential for a Healthier Heart!
October 18, 2024